1. Home
  2. BSL vs PYXS Comparison

BSL vs PYXS Comparison

Compare BSL & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone

BSL

Blackstone

HOLD

Current Price

$12.91

Market Cap

169.3M

Sector

Finance

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$2.64

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSL
PYXS
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
169.3M
141.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BSL
PYXS
Price
$12.91
$2.64
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
38.1K
1.5M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
9.55%
N/A
EPS Growth
N/A
3.03
EPS
N/A
N/A
Revenue
N/A
$13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.45
$0.97
52 Week High
$14.35
$5.55

Technical Indicators

Market Signals
Indicator
BSL
PYXS
Relative Strength Index (RSI) 35.13 56.61
Support Level $12.83 $1.22
Resistance Level $13.00 $2.92
Average True Range (ATR) 0.08 0.29
MACD -0.01 -0.01
Stochastic Oscillator 3.70 48.37

Price Performance

Historical Comparison
BSL
PYXS

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: